Evidence map›Paper›PMID 33793577›Full record

ArticlePloS one2021

Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017).

Scott A Nabity, Laurence J Gunde, Diya Surie, Ray W Shiraishi, Hannah L Kirking, Alice Maida, Andrew F Auld, Michael Odo, Andreas Jahn, Rose K Nyirenda and 1 more

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Scott A NabityGlobal Tuberculosis Prevention and Control Branch, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.ORCID 0000-0002-0170-5649
Laurence J GundeCenter for Global Health, U.S. Centers for Disease Control and Prevention, Lilongwe, Malawi.
Diya SurieGlobal Tuberculosis Prevention and Control Branch, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Ray W ShiraishiGlobal Tuberculosis Prevention and Control Branch, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Hannah L KirkingGlobal Tuberculosis Prevention and Control Branch, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Alice MaidaCenter for Global Health, U.S. Centers for Disease Control and Prevention, Lilongwe, Malawi.
Andrew F AuldCenter for Global Health, U.S. Centers for Disease Control and Prevention, Lilongwe, Malawi.ORCID 0000-0001-5089-9163
Michael OdoDepartment of HIV and AIDS, Malawi Ministry of Health, Lilongwe, Malawi.
Andreas JahnDepartment of HIV and AIDS, Malawi Ministry of Health, Lilongwe, Malawi.
Rose K NyirendaDepartment of HIV and AIDS, Malawi Ministry of Health, Lilongwe, Malawi.
John E OeltmannGlobal Tuberculosis Prevention and Control Branch, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIsoniazid preventive therapy (IPT) against tuberculosis (TB) is a life-saving intervention for people living with HIV (PLHIV). In September 2017, Malawi began programmatic scale-up of IPT to eligible PLHIV in five districts with high HIV and TB burden. We measured the frequency and timeliness of early-phase IPT implementation to inform quality-improvement processes. METHODS AND

findingsWe applied a two-stage cluster design with systematic, probability-proportional-to-size sampling of six U.S. Centers for Disease Control and Prevention (CDC)-affiliated antiretroviral therapy (ART) centers operating in the urban areas of Lilongwe and Blantyre, Malawi (November 2017). ART clinic patient volume determined cluster size. Within each cluster, we sequentially sampled approximately 50 PLHIV newly enrolled in ART care. We described a quality-of-care cascade for intensive TB case finding (ICF) and IPT in PLHIV. PLHIV newly enrolled in ART care were eligibility-screened for hepatitis and peripheral neuropathy, as well as for TB disease using a standardized four-symptom screening tool. Among eligible PLHIV, the overall weighted IPT initiation rate was 70% (95% CI: 46%-86%). Weighted IPT initiation among persons aged <15 years (30% [95% CI: 12%-55%]) was significantly lower than among persons aged ≥15 years (72% [95% CI: 47%-89%]; Rao-Scott chi-square P = 0.03). HIV-positive children aged <5 years had a weighted initiation rate of only 13% (95% CI: 1%-79%). For pregnant women, the weighted initiation rate was 67% (95% CI: 32%-90%), similar to non-pregnant women aged ≥15 years (72% [95% CI: 49%-87%]). Lastly, 95% (95% CI: 92%-97%) of eligible PLHIV started ART within one week of HIV diagnosis, and 92% (95% CI: 73%-98%) of patients receiving IPT began on the same day as ART.

conclusionsEarly-phase IPT uptake among adults at ART centers in Malawi was high. Child uptake needed improvement. National programs could adapt this framework to evaluate their ICF-IPT care cascades.

Indexed as

AdolescentAdultAmbulatory Care FacilitiesAntitubercular AgentsChildChild, PreschoolFemaleHIVHIV InfectionsHumansIsoniazidMalawiMaleMass ScreeningMiddle AgedPregnancyAntitubercular AgentsIsoniazid

Identifiers

PMID33793577
PMCPMC8016323

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.